Skip to main content

Main menu

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • For authors
    • Instructions for authors
    • Submit a manuscript
    • Author FAQs
    • Open access
    • COVID-19 submission information
  • Alerts
  • Podcasts
  • Subscriptions
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

User menu

  • Log in
  • Subscribe
  • Contact Us
  • My Cart

Search

  • Advanced search
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

Login

European Respiratory Society

Advanced Search

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • For authors
    • Instructions for authors
    • Submit a manuscript
    • Author FAQs
    • Open access
    • COVID-19 submission information
  • Alerts
  • Podcasts
  • Subscriptions

Chronic cough and sputum production: a clinical COPD phenotype?

Pierre-Régis Burgel
European Respiratory Journal 2012 40: 4-6; DOI: 10.1183/09031936.00022412
Pierre-Régis Burgel
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: pierre-regis.burgel@cch.aphp.fr
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Chronic obstructive pulmonary disease (COPD) is characterised by incompletely reversible airflow limitation and its severity has been categorised using the level of forced expiratory volume in 1 s (FEV1) [1]. Because marked heterogeneity existed between subjects with comparable FEV1 [2], it has been proposed that identification of subgroups of COPD subjects could represent an alternative to the current FEV1-based classification [3]. A consensus report proposed that COPD phenotypes, as defined by “a single or combination of disease attributes that describes differences between individuals with COPD as they relate to clinically meaningful outcomes (symptoms, exacerbations, response to therapy, rate of disease progression or death)”, could represent the future of COPD [4].

Chronic cough and sputum production (chronic bronchitis) have long been recognised as a consequence of tobacco smoking. In the 1960s, the British hypothesis proposed that chronic cough and sputum production encouraged bronchial infection, which promoted airway and alveolar damage and led to airflow limitation [5]. In their classical study reported in 1976, Fletcher and Peto [6] concluded that while chronic cough and sputum production and airflow limitation both occurred in smokers, they were largely unrelated disease processes. Almost 20 yrs later, Vestbo et al. [7] reported that chronic cough and sputum production were associated with an excess FEV1 decline and increased risk of hospitalisation because of COPD. Data from the Lung Health Study further indicated that chronic cough and sputum production were associated with increased lower respiratory illnesses (exacerbations) in subjects with mild airflow limitation [8]. These two studies shed new light on the potential importance of chronic cough and sputum production in subjects with COPD. They were followed by studies suggesting that chronic cough and sputum production were associated with increased mortality risk [9–11] and exacerbations [12, 13] in COPD patients.

In the present issue of the European Respiratory Journal, Montes de Oca et al. [14] examined the prevalence of chronic bronchitis in subjects with and without COPD identified in a cross-sectional, population-based study in five Latin American cities (PLATINO study). Although the prevalence of chronic bronchitis was rather low in this population, the authors reported that COPD subjects with chronic bronchitis had worse lung function and general health status, and had more respiratory symptoms, physical activity limitation and exacerbations [14]. The authors proposed that chronic bronchitis in COPD subjects was possibly associated with increased disease severity and represented a COPD phenotype [14]. The study by Montes de Oca et al. [14] follows several recent cross-sectional studies that compared clinical characteristics of COPD subjects with and without chronic cough and sputum production [2, 15–17]. These studies yielded somewhat variable results regarding the prevalence of chronic cough and sputum production in COPD subjects and their association with other COPD characteristics or outcomes (table 1).

View this table:
  • View inline
  • View popup
Table 1– Summary of cross-sectional studies that compared clinical characteristics in chronic obstructive pulmonary disease subjects with and without chronic cough and sputum production

Variations in the prevalence of chronic bronchitis among several studies may be related to differences in its definition and to differences in the study populations. Chronic bronchitis is usually defined by “cough and phlegm (or sputum production) most days for >3 months in two consecutive years”. The study by Montes de Oca et al. [14] shows that the use of another definition based on “phlegm on most days for at least 3 months per year for ≥2 yrs” almost doubled the prevalence of chronic bronchitis. Other investigators have defined chronic bronchitis (or chronic mucus hypersecretion) by using a definition based on the “emission of >30 mL of sputum daily at least 3 months a year, for >1 yr” [12, 18]. Because all these definitions were based on expert opinion, it is unclear which one should be adopted. Regardless of the definition used, the prevalence of chronic cough and sputum production consistently increased with increasing airflow limitation [2, 15, 17, 19], and this finding may, in part, account for the low prevalence of chronic bronchitis in the PLATINO study, in which COPD subjects had mild airflow limitation.

Montes de Oca et al. [14] reported that COPD exacerbations were twice as frequent in patients with chronic phlegm production (although this difference was not statistically significant, probably due to lack of power), confirming results obtained in two other studies [15, 16]. However, no association was found between chronic cough and sputum production and exacerbations in the cross-sectional analysis of the ECLIPSE study [2]. During the first year of longitudinal follow-up of the ECLIPSE study, Hurst et al. [20] reported that chronic cough at study entry was associated (OR 1.20, 95% CI 1.01–1.42) with the occurrence of exacerbations, but this association did not remain significant in the multivariate analysis. In the latter study, chronic bronchitis or chronic phlegm production were not associated with exacerbations [20]. Thus, the relationship of chronic cough and/or sputum production to COPD exacerbations, an important clinical outcome, is not consistent among studies. To date, the reasons for these discrepancies remain to be established.

Several studies reported that subjects with chronic cough and sputum production had more severe dyspnoea [14, 16, 17], but these findings were again not reproduced in the ECLIPSE study [2]. Furthermore, it is unclear whether chronic cough and sputum production are independent determinants of dyspnoea in COPD subjects.

Assessment of chronic cough and sputum production relies on patient perception and recollection of symptoms, which is subject to bias. It may be affected by several factors including social behaviour (e.g. females often had lower prevalence of chronic cough and sputum production [2, 17], suggesting that they may be less prone to report such symptoms) and cultural factors in various geographic areas. It is also conceivable that the recent occurrence of a COPD exacerbation, in which cough and sputum production increase, result in increased reporting of chronic cough and sputum production. Furthermore, investigators have consistently reported that chronic cough and sputum production were more prevalent in current versus ex-smokers with COPD [2, 14–17]. These considerations may explain why chronic cough and sputum production were persistent over time in some, but not all, COPD subjects [7, 11], further complicating the understanding of their potential impact.

In the end, can we really consider that chronic cough and sputum production is a clinical COPD phenotype? It is suggested that chronic cough and sputum production cannot in itself be considered as a clinical COPD phenotype because: 1) conflicting data exist regarding its association with important clinical manifestations (e.g. dyspnoea) and outcomes (e.g. exacerbations); and 2) the two studies suggesting that chronic bronchitis was associated with increased mortality in COPD subjects will require confirmation before any definitive conclusion can be made [9, 11]. However, it is likely that chronic cough and sputum production are not innocent symptoms and may help in identifying specific COPD phenotypes. Interesting data supporting this view come from the results of recent clinical trials. Post hoc analysis of studies assessing the efficacy of roflumilast (a phosphodiesterase-4 inhibitor) [21, 22] or pulsed moxifloxacin [23] for the prevention of COPD exacerbations suggested that these interventions were efficacious in the subset of COPD subjects with chronic cough and/or sputum production at study entry. Such post hoc analyses have been used to define characteristics of patients included in a prospective clinical trial that demonstrated the reduction of exacerbations by roflumilast in a specific subset of COPD subjects [22, 24]. These subjects with severe airflow limitation (FEV1 <50% predicted), repeated exacerbations and chronic cough and sputum production experienced improvement with roflumilast [24], whereas no effect was found when selecting subjects only on the basis of severe airflow limitation [21].

Finally, COPD is a very heterogeneous disease and it seems unlikely that a single disease attribute would be sufficient to identify a specific patient phenotype. A working hypothesis is that the combination of multiple characteristics (including gene–environment data, age, comorbidities, imaging, biomarkers, etc.) and their analysis using mathematical techniques may be more suitable for the identification of clinically meaningful COPD phenotypes [25–27].

Footnotes

  • Statement of Interest

    A statement of interest for P-R. Burgel can be found at www.erj.ersjournals.com/site/misc/statements.xhtml

  • ©ERS 2012

REFERENCES

  1. ↵
    Global Inibitative for Obstructive Lung Disease. Global Strategy for the Diagnosis, Management and Prevention of Chronic Obstructive Pulmonary Disease. 2011. www.goldcopd.org Date last accessed: January 7, 2012.
  2. ↵
    1. Agusti A,
    2. Calverley PM,
    3. Celli B,
    4. et al
    . Characterisation of COPD heterogeneity in the ECLIPSE cohort. Respir Res 2010; 11: 122.
    OpenUrlPubMed
  3. ↵
    1. Agusti A,
    2. Celli B
    . Avoiding confusion in COPD: from risk factors to phenotypes to measures of disease characterisation. Eur Respir J 2011; 38: 749–751.
    OpenUrlFREE Full Text
  4. ↵
    1. Han MK,
    2. Agusti A,
    3. Calverley PM,
    4. et al
    . Chronic obstructive pulmonary disease phenotypes: the future of COPD. Am J Respir Crit Care Med 2010; 182: 598–604.
    OpenUrlCrossRefPubMedWeb of Science
  5. ↵
    1. Anthonisen NR
    . The British hypothesis revisited. Eur Respir J 2004; 23: 657–658.
    OpenUrlFREE Full Text
  6. ↵
    1. Fletcher C,
    2. Peto R
    . The natural history of chronic airflow obstruction. BMJ 1977; 1: 1645–1648.
    OpenUrlAbstract/FREE Full Text
  7. ↵
    1. Vestbo J,
    2. Prescott E,
    3. Lange P
    . Association of chronic mucus hypersecretion with FEV1 decline and chronic obstructive pulmonary disease morbidity. Copenhagen City Heart Study Group. Am J Respir Crit Care Med 1996; 153: 1530–1535.
    OpenUrlCrossRefPubMedWeb of Science
  8. ↵
    1. Kanner RE,
    2. Anthonisen NR,
    3. Connett JE
    . Lower respiratory illnesses promote FEV1 decline in current smokers but not ex-smokers with mild chronic obstructive pulmonary disease: results from the lung health study. Am J Respir Crit Care Med 2001; 164: 358–364.
    OpenUrlCrossRefPubMedWeb of Science
  9. ↵
    1. Ekberg-Aronsson M,
    2. Pehrsson K,
    3. Nilsson JA,
    4. et al
    . Mortality in GOLD stages of COPD and its dependence on symptoms of chronic bronchitis. Respir Res 2005; 6: 98–107.
    OpenUrlCrossRefPubMed
    1. Lange P,
    2. Nyboe J,
    3. Appleyard M,
    4. et al
    . Relation of ventilatory impairment and of chronic mucus hypersecretion to mortality from obstructive lung disease and from all causes. Thorax 1990; 45: 579–585.
    OpenUrlAbstract/FREE Full Text
  10. ↵
    1. Pelkonen M,
    2. Notkola IL,
    3. Nissinen A,
    4. et al
    . Thirty-year cumulative incidence of chronic bronchitis and COPD in relation to 30-year pulmonary function and 40-year mortality: a follow-up in middle-aged rural men. Chest 2006; 130: 1129–1137.
    OpenUrlCrossRefPubMedWeb of Science
  11. ↵
    1. Miravitlles M,
    2. Guerrero T,
    3. Mayordomo C,
    4. et al
    . Factors associated with increased risk of exacerbation and hospital admission in a cohort of ambulatory COPD patients: a multiple logistic regression analysis. Respiration 2000; 67: 495–501.
    OpenUrlCrossRefPubMedWeb of Science
  12. ↵
    1. Seemungal TA,
    2. Donaldson GC,
    3. Paul EA,
    4. et al
    . Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1998; 157: 1418–1422.
    OpenUrlCrossRefPubMedWeb of Science
  13. ↵
    1. Montes de Oca M,
    2. Halbert RJ,
    3. Lopez MV,
    4. et al
    . The chronic bronchitis phenotype in subjects with and without COPD: the PLATINO study. Eur Respir J 2012; 40: 28–36.
    OpenUrlAbstract/FREE Full Text
  14. ↵
    1. Burgel PR,
    2. Nesme-Meyer P,
    3. Chanez P,
    4. et al
    . Cough and sputum production are associated with frequent exacerbations and hospitalizations in COPD subjects. Chest 2009; 135: 975–982.
    OpenUrlCrossRefPubMedWeb of Science
  15. ↵
    1. Kim V,
    2. Han MLK,
    3. Vance GB,
    4. et al
    . The chronic bronchitic phenotype of COPD: an analysis of the COPDGene study. Chest 2011; 140: 626–633.
    OpenUrlCrossRefPubMed
  16. ↵
    1. Lu M,
    2. Yao WZ,
    3. Zhong NS,
    4. et al
    . Chronic obstructive pulmonary disease in the absence of chronic bronchitis in China. Respirology 2010; 15: 1072–1078.
    OpenUrlCrossRefPubMedWeb of Science
  17. ↵
    1. Prescott E,
    2. Lange P,
    3. Vestbo J
    . Chronic mucus hypersecretion in COPD and death from pulmonary infection. Eur Respir J 1995; 8: 1333–1338.
    OpenUrlAbstract
  18. ↵
    1. Vestbo J,
    2. Lange P
    . Can GOLD stage 0 provide information of prognostic value in chronic obstructive pulmonary disease? Am J Respir Crit Care Med 2002; 166: 329–332.
    OpenUrlCrossRefPubMedWeb of Science
  19. ↵
    1. Hurst JR,
    2. Vestbo J,
    3. Anzueto A,
    4. et al
    . Susceptibility to exacerbation in chronic obstructive pulmonary disease. N Engl J Med 2010; 363: 1128–1138.
    OpenUrlCrossRefPubMedWeb of Science
  20. ↵
    1. Calverley PMA,
    2. Sanchez-Torill F,
    3. McIvor A,
    4. et al
    . Effect of 1-year treatment with roflumilast in severe chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2007; 176: 154–161.
    OpenUrlCrossRefPubMedWeb of Science
  21. ↵
    1. Rennard SI,
    2. Calverley PMA,
    3. Goehring UM,
    4. et al
    . Reduction of exacerbations by the PDE4 inhibitor roflumilast – the importance of defining different subsets of patients with COPD. Respir Res 2011; 12: 18.
    OpenUrlCrossRefPubMed
  22. ↵
    1. Sethi S,
    2. Jones PW,
    3. Theron MS,
    4. et al
    . Pulsed moxifloxacin for the prevention of exacerbations of chronic obstructive pulmonary disease: a randomized controlled trial. Respir Res 2010; 11: 10.
    OpenUrlCrossRefPubMed
  23. ↵
    1. Calverley PM,
    2. Rabe KF,
    3. Goehring UM,
    4. et al
    . Roflumilast in symptomatic chronic obstructive pulmonary disease: two randomised clinical trials. Lancet 2009; 374: 685–694.
    OpenUrlCrossRefPubMedWeb of Science
  24. ↵
    1. Kaminsky DA,
    2. Irvin CG,
    3. Sterk PJ
    . Complex systems in pulmonary medicine: a systems biology approach to lung disease. J Appl Physiol 2011; 110: 1716–1722.
    OpenUrlAbstract/FREE Full Text
    1. Burgel PR,
    2. Paillasseur JL,
    3. Caillaud D,
    4. et al
    . Clinical COPD phenotypes: a novel approach using principal component and cluster analyses. Eur Respir J 2010; 36: 531–539.
    OpenUrlAbstract/FREE Full Text
  25. ↵
    1. Weatherall M,
    2. Travers J,
    3. Shirtcliffe PM,
    4. et al
    . Distinct clinical phenotypes of airways disease defined by cluster analysis. Eur Respir J 2009; 34: 812–818.
    OpenUrlAbstract/FREE Full Text
View Abstract
PreviousNext
Back to top
View this article with LENS
Vol 40 Issue 1 Table of Contents
European Respiratory Journal: 40 (1)
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
Email

Thank you for your interest in spreading the word on European Respiratory Society .

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Chronic cough and sputum production: a clinical COPD phenotype?
(Your Name) has sent you a message from European Respiratory Society
(Your Name) thought you would like to see the European Respiratory Society web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Print
Alerts
Sign In to Email Alerts with your Email Address
Citation Tools
Chronic cough and sputum production: a clinical COPD phenotype?
Pierre-Régis Burgel
European Respiratory Journal Jul 2012, 40 (1) 4-6; DOI: 10.1183/09031936.00022412

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Chronic cough and sputum production: a clinical COPD phenotype?
Pierre-Régis Burgel
European Respiratory Journal Jul 2012, 40 (1) 4-6; DOI: 10.1183/09031936.00022412
del.icio.us logo Digg logo Reddit logo Technorati logo Twitter logo CiteULike logo Connotea logo Facebook logo Google logo Mendeley logo
Full Text (PDF)

Jump To

  • Article
    • Footnotes
    • REFERENCES
  • Figures & Data
  • Info & Metrics
  • PDF

Subjects

  • COPD and smoking
  • Tweet Widget
  • Facebook Like
  • Google Plus One

More in this TOC Section

  • Nefer, Sinuhe and clinical research assessing post-COVID-19 syndrome
  • Asthma and COVID-19: do we finally have answers?
  • Is low level of vitamin D a marker of poor health or its cause?
Show more Editorial

Related Articles

Navigate

  • Home
  • Current issue
  • Archive

About the ERJ

  • Journal information
  • Editorial board
  • Reviewers
  • CME
  • Press
  • Permissions and reprints
  • Advertising

The European Respiratory Society

  • Society home
  • myERS
  • Privacy policy
  • Accessibility

ERS publications

  • European Respiratory Journal
  • ERJ Open Research
  • European Respiratory Review
  • Breathe
  • ERS books online
  • ERS Bookshop

Help

  • Feedback

For authors

  • Instructions for authors
  • Submit a manuscript
  • ERS author centre

For readers

  • Alerts
  • Subjects
  • Podcasts
  • RSS

Subscriptions

  • Accessing the ERS publications

Contact us

European Respiratory Society
442 Glossop Road
Sheffield S10 2PX
United Kingdom
Tel: +44 114 2672860
Email: journals@ersnet.org

ISSN

Print ISSN:  0903-1936
Online ISSN: 1399-3003

Copyright © 2021 by the European Respiratory Society